In a report released on August 11, Colleen M. Kusy from Robert W. Baird maintained a Buy rating on Oric Pharmaceuticals (ORIC – Research Report), with a price target of $15.00. The company’s shares closed yesterday at $4.71.
According to TipRanks, M. Kusy is an analyst with an average return of -28.6% and a 22.31% success rate. M. Kusy covers the Healthcare sector, focusing on stocks such as IVERIC bio, AVEO Pharma, and Karyopharm Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Oric Pharmaceuticals with a $12.00 average price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $26.70 and a one-year low of $2.62. Currently, Oric Pharmaceuticals has an average volume of 319.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely, ORIC-101 and ORIC-533.
Read More on ORIC:
- Robert W. Baird Gives a Buy Rating to Toast Inc (TOST)
- Robert W. Baird Gives a Buy Rating to Taysha Gene Therapies (TSHA)
- Robert W. Baird Gives a Buy Rating to Marinus (MRNS)
- Robert W. Baird Issues a Buy Rating on Vor Biopharma (VOR)
- Global Payments (GPN): New Buy Recommendation for This Technology Giant
